Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Avalyn Pharma Inc. (AVLN)

Avalyn Pharma expands Boston sublease to 13,708 sq ft, adds about $924,000 in lease payments

Neutral Impact 2 of 5 product/contract Written later

Avalyn Pharma entered a First Amendment to its sublease with CRISPR Therapeutics, effective June 29, 2026, expanding the Boston premises from about 8,774 to about 13,708 rentable square feet. The amendment raises the company's future minimum lease payments by approximately $924,000 over the remaining lease term, a modest commitment that shareholders may want to note.

Key points

  • Effective date: June 29, 2026; the sublease covers 105 West First Street, Boston, Massachusetts
  • Premises expand from approximately 8,774 to approximately 13,708 rentable square feet
  • Future minimum lease payments increase by approximately $924,000 over the remaining lease term
  • All other terms of the original August 29, 2025 sublease remain in effect

The filing

CompanyAvalyn Pharma Inc. (AVLN)
Form8-K, current report
Filed with the SECJul 1, 2026, 5:20 PM ET
Accession number0001193125-26-292834

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.